Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients

Table 4 Post hoc comparison for the chemotherapy factor between the different groups of tamoxifen use duration

Variables	Groups	Mean ± SD		*p-value	95% Wald Confidence Interval
		Without CT	With CT		Without CT		With CT
					Lower	Upper	Lower	Upper
BMI	1	25.29¹ ± 0.46	29.14 ± 0.93	0.003	24.41	26.20	27.39	31.02
	2	28.40¹ ± 0.95	26.76 ± 0.85	0.720	26.60	30.33	25.14	28.48
	3	21.97 ± 3.18	26.27 ± 0.83	0.720	16.55	29.18	24.70	27.94
WC	1	85.84² ± 0.90	94.45 ± 1.96	0.001	84.10	87.62	90.68	98.38
	2	97.75^2,4 ± 0.88	91.07 ± 2.44	0.105	96.03	99.50	86.41	95.97
	3	76.00⁴ ± 7.02	88.46 ± 2.07	0.429	63.40	91.10	84.49	92.61
BFP	1	30.32³ ± 0.43	36.36 ± 1.50	0.001	29.49	31.18	33.54	39.41
	2	42.95³ ± 1.03	33.43 ± 1.66	0.000	40.98	45.00	30.34	36.84
	3	36.30 ± 5.73	35.47 ± 1.65	0.988	26.64	49.47	32.39	38.85

¹ p = 0.042; ² p = 0.000; ³ p = 0.000; ⁴ p = 0.025; BMI, Body Mass Index; WC, waist circumference; BFP, body fat percentage; CT, chemotherapy; SD, Standard Deviation; Group 1, women using tamoxifen for the first 3 years; Group 2, women using tamoxifen between 3 and 4 years; Group 3, women using TMX for more than 4 years. Data adjusted for age, smoking, alcohol consumption, physical activity, energy (kcal), and clinical stage. *p calculated by ANOVA. Post hoc comparison (Sidak method)

ISSN: 1471-2407